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http://dx.doi.org/10.1016/j.ccell.2014.11.009SUMMARYThe dominant TLR5R392X polymorphism abrogates flagellin responses in >7% of humans. We report that
TLR5-dependent commensal bacteria drive malignant progression at extramucosal locations by increasing
systemic IL-6, which drives mobilization of myeloid-derived suppressor cells (MDSCs). Mechanistically,
expanded granulocytic MDSCs cause gd lymphocytes in TLR5-responsive tumors to secrete galectin-1,
dampening antitumor immunity and accelerating malignant progression. In contrast, IL-17 is consistently
upregulated in TLR5-unresponsive tumor-bearing mice but only accelerates malignant progression in
IL-6-unresponsive tumors. Importantly, depletion of commensal bacteria abrogates TLR5-dependent
differences in tumor growth. Contrasting differences in inflammatory cytokines and malignant evolution
are recapitulated in TLR5-responsive/unresponsive ovarian and breast cancer patients. Therefore, inflam-
mation, antitumor immunity, and the clinical outcome of cancer patients are influenced by a common
TLR5 polymorphism.INTRODUCTION
A rapidly growing paradigm is that commensal microorganisms
are required to maintain immune homeostasis of mucosal
surfaces suchas the intestine (Mazmanianet al., 2008)while facil-
itating the shaping of immune responses against pathogens in
the periphery (Abt et al., 2012; Clarke et al., 2010). Most recently,
interactions between microbiota and mucosal surfaces haveSignificance
7.5% of the general population harbor a single dominant nucleo
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sponses for tumors occurring outside of the intestinal tract (Iida
et al., 2013; Viaud et al., 2013). Although themechanismsof distal
immune regulation by themicrobiota are poorly understood, their
importance is illustrated by the lack of cellular immune responses
and a very narrow T cell repertoire in germ-free mice.
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Figure 1. Tumor-Promoting Inflammation Is Driven by TLR5-Dependent Signaling
(A–C) Serum levels of IL-6 (A), IL-23 (B), and CCL3 (C) in TLR5-responsive (WT) and TLR5-deficient (Tlr5/) mice with advanced (days 64–75) flank sarcomas
(Tumor, nR 15/group) or naive littermate controls, as detected by ELISA.
(D and E) Proportions (D) and total numbers (E) of MDSC infiltrating into the spleens of WT or Tlr5/ mice bearing equally sized tumors. Shown is one repre-
sentative of two independent experiments with five to eight animals per group.
(F) IFNg enzyme-linked Immunospot of sorted antigen-specific CD8 T cells from the draining lymph node (inguinal) of mice bearing day 64 hind flank sarcomas
incubated with tumor-lysated, pulsed BMDCs (pulsed) or BMDCs only (unpulsed). Data are representative of two experiments with at least three mice per group.
(G) Representative images of tumors and growth curve of Tlr5/ or WT transgenic mice administered subcutaneous adenovirus-Cre into the hind flank. Data are
representative of five individual experiments with at least six to ten mice per group.
(H) Representative final tumor volume and resected ID8-Vegf-Defb29 tumors 27 days after injection into the axillary flank. Data are representative of two individual
experiments with at least five to eight mice per group.
(legend continued on next page)
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TLR5 Signaling Drives Tumor-Promoting Inflammationmicrobiota. At least 23% of individuals in the general population
are carriers of functional polymorphisms in Toll-like receptor
(TLR) genes (Casanova et al., 2011), but their effect on immuno-
surveillance against extraintestinal tumors remains poorly under-
stood. One of the most frequent polymorphisms is found in
TLR5. Approximately 7.5% of the general population harbor
a single dominant nucleotide polymorphism in TLR5 (1174
C > T), encoding a stop codon in place of an arginine at codon
392 (TLR5R392X) (Hawn et al., 2003; Misch and Hawn, 2008).
This polymorphism results in truncating the transmembrane
signaling domain of TLR5 (the specific receptor of flagellin),
abrogating signaling by 50%–80%, even for individuals who
are heterozygous for this allele. Although the relative frequency
of heterozygous carriers within the general population indicates
compatibility with a healthy lifestyle, this polymorphism has
immunological consequences because heterozygous carriers
have an enhanced susceptibility to Legionnaires disease
(Hawn et al., 2003), urinary tract infections (Hawn et al., 2009),
and bronchopulmonary dysplasia (Sampath et al., 2012).
However, virtually nothing is known about the systemic con-
sequences of microbially induced TLR5-dependant signaling,
and malignant progression of tumors occurring outside of the
intestines.
Here we dissected the role of TLR5 signaling at mucosal sur-
faces on tumor progression at extramucosal locations through
systemic inflammation.
RESULTS
TLR5 Signaling Results in Tumor-Promoting Systemic
Inflammatory Responses during Malignant Progression
To determine whether TLR5 signaling influences the malignant
progression of extraintestinal tumors, we generated B6
mice with latent mutations in p53 and K-ras (Trp53flx/flx;LSL-
KrasG12D/+) (Jackson et al., 2001; Jonkers et al., 2001; Scarlett
et al., 2012) on a TLR5-deficient (Tlr5/) or TLR5-responsive
(wild-type [WT]) background. No evidence of metabolic syn-
drome or colitis in Tlr5/ mice was observed in our facilities
(Figures S1A–S1C available online). Subcutaneous delivery of
adenoviruses expressing Cre-recombinase into the hind flank
led to concurrent ablation of p53 and activation of oncogenic
K-ras, resulting in palpable tumors with histological features of
sarcoma. Notably, tumor-bearing (but not naive) WT mice ex-
hibited significantly greater serum levels of IL-6 compared with
Tlr5/ littermates bearing similarly sized tumors (Figure 1A; Fig-
ure S1D), whereas other inflammatory cytokines were increased
at similar levels or remained unchanged in both groups (Figures
1B and 1C; Figures S1E and S1F).
Consistent with IL-6-mediated systemic inflammation, we
found increased mobilization of myeloid-derived suppressor
cells (MDSCs) (Figures 1D an 1E)—both Ly6C+ and Ly6G+
(Figure S1G)—in TLR5-responsive mice compared with Tlr5/
littermates with an equivalent tumor burden. As expected,
no TLR5-dependent differences were found in tumor-free mice(I) Growth curve and representative resected UPK10 (p53/K-ras-dependent ovaria
two individual experiments with at least four to six mice per group.
(J) Survival proportions of Tlr5/ and WT mice bearing syngenic ID8 ovarian tum
All data represent the mean ± SEM. *p < 0.05, ***p < 0.001 Tlr5/ compared with(Figure S1H). Reconstitution with IL-6-deficient bone marrow
(Figure S1I) and antibody-mediated neutralization of IL-6 (Fig-
ure S1J) resulted in significant decreases in the mobilization of
MDSCs in tumor-bearing WT hosts. Accordingly, tumor-specific
effector CD8 T cell responses were significantly impaired in WT
animals (Figure 1F) but were restored in tumor-bearing WT ani-
mals reconstituted with IL-6-deficient bonemarrow (Figure S1K).
Correspondingly, tumor growth was increased in TLR5-compe-
tent hosts (Figure 1G).
Accelerated malignant progression in TLR5-responsive mice
was not driven by TLR5-dependent responses in the tumor
cells (e.g., in response to bacterial translocation), as the same
tumor cells, or syngeneic p53/K-ras ovarian tumor-derived cells
(Scarlett et al., 2012) injected into the axillary flank also pro-
gressed significantly faster in TLR5-responsive mice, compared
to TLR5-deficient littermates (Figures 1H and 1I). Differences
in tumor progression (Figure 1J) and antitumor immunity (Fig-
ure S1L) were also recapitulated when ovarian tumor cells
were administered intraperitoneally.
No endotoxin could be detected in the serum or tumor ascites
(data not shown). More importantly, the background PCR signals
for bacterial ribosomal 16S detected in the serum, tumor,
draining lymph nodes, or ascites from WT or Tlr5/ mice were
similar to those found in matching control samples from healthy
WT mice (Figure S1M).
Taken together, these data indicate that TLR5 signaling is
sufficient to drive systemic tumor-promoting inflammation
associated with impaired antitumor immunity and accelerated
malignant progression and without obvious dysbiosis in TLR5-
deficient hosts.
TLR5-Dependent Accelerated Extraintestinal
Tumor Growth Is Mediated through Interactions
with Commensal Microbiota
Notably, although the composition of the microbiota in TLR5-
deficient and TLR5-competent mice was more similar than
when compared individually with WT syngeneic mice from a
different facility within the campus of the University of Pennsylva-
nia, microbiome-wide differences remained between WT and
Tlr5/mice after cohousing them in the same cage for 4 weeks
(Figures 2A and 2B). Significant differences were found in the
genera of Allobaculum,Bacteroides, and Lactobacillus, although
not in other species associated with inflammation, such as
Candidatus Arthromitus or Clostridia. In addition, cohoused
WT and Tlr5/ mice retained differences in the progression of
both ovarian tumors and transplantable sarcomas generated
from p53/K-ras autochthonous tumors (termed MPKAS; Figures
2C–2F). Because mice are naturally coprophagic, differences in
the composition of the microbiota after cohousing suggest that
the absence of TLR5 activity contributes to forge a dissimilar
repertoire of commensal bacteria under similar environmental
conditions. To test the influence of TLR5-dependent commensal
microorganisms on the progression of extramucosal tumors,
we first confirmed significantly elevated serum levels of IL-6n) tumors 43 days after challenge in the axillary flank. Data are representative of
or cells (R5/group with two repetitions).
WT using Mann-Whitney test and log rank test for survival. See also Figure S1.
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Figure 2. The Absence of TLR5 Signaling Results in a Divergent Microbial Composition and Reduced Tumor Progression
(A) Heatmap of operational taxonomic units of commensal bacterial phyla fromWT or Tlr5/mice cohoused for 4 weeks comparedwith naiveWTmice housed in
a different animal facility (WT other).
(B) Proportions of the indicated bacterial phyla in cohoused WT and Tlr5/ mice. Boxes represent the interquartile range (bottom, 25th percentile; top,
75th percentile), and the line inside represents the median. Whiskers denote the lowest and highest values within 1.53 the interquartile range. Kruskal-Wallis
one-way ANOVA was used to calculate significance.
(C) Tumor growth kinetics of ID8-Vegf-Defb29 injected into the axillary flank of WT and Tlr5/ mice cohoused for 4 weeks prior to the injection. Data are
representative of one experiment with at least five mice per group.
(D) Tumors from cohoused mice in (C) resected after 69 days.
(E) Growth kinetics of MPKAS sarcomas injected in the axillary flank of WT and Tlr5/mice cohoused for 3 weeks prior to the injection. Data are representative
of one experiment with at least five mice per group.
(F) Resected tumors from cohoused mice in (C) 14 days after injection.
All data represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Unless stated otherwise, Mann-Whitney test was used.
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TLR5 Signaling Drives Tumor-Promoting Inflammation(Figure 3A) and accelerated tumor growth (Figure 3B) in WTmice
challenged with transplantable MPKAS sarcomas. Depletion of
commensal microbiota in both TLR5-responsive and deficient30 Cancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc.mice by oral administration of antibiotics (ABX) resulted in
enlarged ceca and a reduction in the burden of bacteria in the
intestines, as evidenced by 16 s quantification of the bacterial
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CB Figure 3. Commensal Microbiota Modulate
TLR5-Dependent Tumor Growth through
Increased IL-6 and gd T Cells
(A) IL-6 serum levels of WT or Tlr5/mice 14 days
after being transplanted with the MPKAS sarcoma
cell line.
(B) Tumor volume of MPKAS in Tlr5/ or WT mice
at day 14 (nR 26/group).
(C–E) WT and Tlr5/mice were gavaged daily for
2 weeks with an antibiotic cocktail (ABX) to elimi-
nate the commensalmicrobiota or with autoclaved
H2O prior to the initiation of MPKAS tumors, and
antibiotic depletion was continued throughout
the course of tumor progression. IL-6 serum levels
in mice 14 days after initiation of MPKAS tumors
(C), tumor growth kinetics (D), and total gd T cells
in the draining axillary and brachial lymph node
in mice 14 days after initiation of MPKAS tumors
(E) are shown. Data are representative of at least
three experiments with five mice per group.
(F) Growth kinetics of MPKAS tumors in Tcrd/ or
Tlr5//Tcrd/ mice compared with the appro-
priate WT and Tlr5/ littermate controls. Data
are representative of two individual experiments
with at least five to eight mice per group.
(G) Volume of tumors 14 days after transplantation
of MPKAS tumor cells alone or together with WT
or Tlr5/ tumor-associated gd T cells into the
auxiliary flank of naive WT mice.
(H) Tumor growth curve of MPKAS cells admixed
with tumor-associated gd T cells sorted from
WT or Tlr5/ tumor-bearing mice injected into
the axillary flank of Tcrd/ or Tlr5//Tcrd/
mice and representative resected tumors 14 days
after the implantation.
(I) Total galectin-1+ gd T cells from tumor-draining
lymph nodes of WT or Tlr5/mice with advanced
autochthonous sarcomas.
(J) gd T cells were sorted from the draining lymph
nodes of WT or Tlr5/ mice bearing advanced
autochthonous sarcomas and cultured for 6 hr
with phorbol 12-myristate 13-acetate/ionomycin.
Supernatants were collected and assayed for
galectin-1 levels.
All data represent the mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001 using Mann-Whitney test.
See also Figure S2.
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S2A and S2B). Most importantly, differences in systemic IL-6
levels (Figure 3C), mobilization of MDSCs (Figure S2C), and
tumor growth (Figure 3D; Figure S2D) were all completely
abrogated when commensal bacteria were eliminated from tu-
mor-challenged WT and Tlr5/ mice as a result of significantly
delayed tumor progression in WTmice. Correspondingly, bacte-
rial depletion was associated with an increased accumulation
of interferong (IFNg)-producing effector CD8 T cells (Figure S2E).
Decreased tumor growth could not be attributed to nonspecific
antitumor activity of the (oral) antibiotic cocktail because there
was no effect on tumor cell proliferation (Figure S2F).
gd T Cells Promote Tumor Growth through Galectin-1
Secretion in a TLR5-Dependent Manner
Unexpectedly, bacterial depletion resulted in a significant and
selective decrease in the number of gd T cells in the tumormicroenvironment (TME) in TLR5-responsive hosts (Figure 3E;
Figure S2G). gd lymphocytes preferentially accumulate at
mucosal surfaces, linking innate and adaptive immunity through
the secretion of cytokines and chemokines, providing help for
adaptive responses, lysing target cells, or directly presenting
antigens.
To understand the role of gd T cells infiltrating into tumors that
grow more aggressively in the presence of TLR5 signaling, WT
and Tlr5/ littermates deficient of gd T cells were challenged
with syngeneic MPKAS sarcomas. Tumors progressed signifi-
cantly more slowly in WT mice lacking gd T cells, whereas tumor
growth in Tlr5/ gd-deficient mice was unchanged (Figure 3F).
To verify that tumor-derived gd T cells were sufficient to accel-
erate malignant growth only in the presence of TLR5 signaling,
gd T cells were sorted from the draining lymph nodes of WT
and Tlr5/mice with advanced autochthonous p53/K-ras flank
sarcomas and admixed with MPKAS tumor cells for injectionCancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc. 31
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tered alone and together with tumor-derived gd T cells from
Tlr5/ mice, gd T cells from WT mice significantly accelerated
tumor growth (Figure 3G). Correspondingly, administration of
tumor-associated gd T cells from TLR5-responsive mice (but
not from Tlr5/ mice) enhanced tumor growth in gd T cell-defi-
cient mice (Figure 3H). However, acceleratedmalignant progres-
sion only occurred in TLR5-responsive hosts, suggesting that
intrinsic TLR5-dependent mechanisms regulate the tumor-pro-
moting activity of gd T cells.
An exhaustive phenotypic analysis of gd T cells sorted from
tumors and draining lymph nodes of WT and Tlr5/ mice did
not reveal significant differences in the levels of NKG2D, CD39/
CD73, and PD-1 or in the production of IL-10, IFNg, PGE2,
perforin, and IL-2 (Figures S2H–S2K). In contrast, as detectable
by intracellular flow cytometry (Figure 3I) and ELISA (Figure 3J),
tumor-associated gd T cells from WT mice produced signifi-
cantly more immunosuppressive galectin-1. Additionally, antibi-
otic treatment of mice also resulted in a significant reduction
in galectin-1-producing gd T cells (Figure S2L). Galectin-1 is a
pleiotropic molecule that binds to surface glycoconjugates
that contain N-acetyllactosamine sequences, promoting their
crosslinking. Because of the dissimilar glycosylation pattern of
different subsets of T helper and effector cells, galectin-1 exerts
apoptosis and unresponsiveness on Th1, Th17, and CD8
effector T cells but enhances regulatory T cell activity (Dalotto-
Moreno et al., 2013; Rubinstein et al., 2004; Toscano et al.,
2007).
Interestingly, exposure of gd T cells to granulocytic
Ly6ClowLy6G+ MDSCs sorted from both WT and Tlr5/ tumor-
bearing hosts induced a significant upregulation of galectin-1
to a greater extent than monocytic Ly6C+Ly6G- MDSCs sorted
from the same hosts or Gr1+CD11b+ myeloid cells sorted
from the spleens of tumor-free mice, whereas control bone
marrow-derived dendritic cells (BMDCs) had negligible effects
(Figures 4A–4C). Transwell experiments demonstrated that
this was attributable to soluble mediators (Figures 4A and 4B)
that were not upregulated by IL-6 or flagellin signaling (Fig-
ure S3A). Notably, incubation of naive gd T cells with different
agonists of adenosine, generated at higher levels by granulocytic
(compared with monocytic) MDSCs (Ryzhov et al., 2011)
increased the proportion of galectin-1+ lymphocytes, whereas
IL-6, PGE2, or transforming growth factor b alone had no
significant effect (Figure S3B). Consequently, depletion of
MDSCs in sarcoma-bearing mice resulted in a significant
decrease in gd T cell-derived galectin-1 (Figure 4D), reducing
the differences in the growth of tumors between Tlr5/ and
WT mice (Figure 4E). Together, these data indicate that MDSCs
preferentially mobilized in response to TLR5-dependent, micro-
biota-driven inflammation and induce gd T cells in the TME to
produce immunosuppressive galectin-1 through soluble factors,
including adenosine, causing accelerated tumor growth.
Galectin-1 Secretion Specifically by
Immunosuppressive gd T Cells Is Sufficient
to Accelerate Tumor Growth
As expected, tumors grew more slowly in galectin-1-deficient
(Lgals1/) mice (Figures S3C and S3D). Other tumor-infiltrating
cells, including MDSCs, also produced galectin-1, although32 Cancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc.at lower levels (Figure S3E). To define whether galectin-1 specif-
ically produced by gd T cells contributed significantly to differen-
tial tumor growth, we generated chimeras with gd- and galectin-
1-deficient mixed bone marrow in p53/K-Ras mice, which were
subsequently challenged with adenovirus-Cre to induce tumor
formation. As shown in Figure 4F, tumors progressed sig-
nificantly more slowly when the only gd T cells in the host were
galectin-1-deficient, without defects in the reconstitution of
the gd T cell compartment (Figure S3F). Furthermore, MPKAS
tumor cells admixed with galectin-1-deficient gd T cells from
tumor-draining lymph nodes grew significantly slower than
MPKAS cells admixed with galectin-1+ gd T cells derived from
tumors of identical size or even MPKAS tumors alone (Figures
S3G and S3H).
To determine whether galectin-1-producing, tumor-derived gd
T cells inhibit antigen-specific T cell responses, gd T cells were
again sorted from tumor-bearing hosts. As shown in Figure 4G,
the antigen-specific proliferation of endogenous tumor-reactive
T cells in response to BMDCs pulsed with UV light- and g-irradi-
ated (immunogenic) tumor cells was impaired significantly in
the presence of gd T cells from syngeneic and autochthonous
tumor-bearing, TLR5-responsive mice, whereas gd T cells
from tumor-bearing Tlr5/ hosts did not significantly inhibit pro-
liferation. Most importantly, gd T cells from WT tumor-bearing
hosts impaired the strong proliferation of ovalbumin-specific
T cells, whereas their counterparts in galectin-1-deficient mice
had no suppressive effect (Figure 4H). Taken together, these
data indicate that gd T cells in TLR5-responsive, but not TLR5-
deficient, tumor-bearing hosts are capable of suppressing
T cell responses by secreting galectin-1, significantly contrib-
uting to malignant progression.
Accelerated Malignant Progression in TLR5-Competent
Hosts Depends on Tumor-Derived IL-6
Our results so far indicated that TLR5 signaling at places of
bacterial colonization in tumor-bearing hosts induced tumor-
promoting systemic inflammation, resulting in the mobilization
of MDSCs and immunosuppressive gd T cells. To define the
general applicability of these findings, WT and Tlr5/ mice
were challenged with multiple tumor models, and the growth
was compared. TC-1 cells and ovarian cancer cell lines gener-
ated from a p53/K-ras model (Scarlett et al., 2012) grew signifi-
cantly faster in TLR5-competent syngeneic mice (Figure 1I and
data not shown). Unexpectedly, syngeneic A7C11 mammary tu-
mor cells, derived from autochthonous p53/K-ras-dependent
mammary carcinomas (Rutkowski et al., 2014), progressed
faster in TLR5-deficient mice in multiple independent experi-
ments (Figure 5A). Serum levels of IL-6 in this system were
much lower than in tumors that progressed more rapidly in WT
mice and were independent of tumor burden or TLR5 signaling
(Figure 5B). Comparable results were obtained with different
clones derived from autochthonous mammary tumors concur-
rently carrying myristoylated (constitutively activated) p110a
(termed BRPKP110 cells; Figure S4A). Notably, exogenous
IL-6 had negligible effects on the upregulation of IL-6 in A7C11
cells (Figure 5C), although STAT3 was effectively activated (Fig-
ure S4B), and tumor cells expressed the IL-17 receptor, IL-6,
receptor and gp300 (Figures S4C and S4D). In contrast, tumors
that induced TLR5-dependent systemic IL-6 upregulation
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B Figure 4. Galectin-1-Producing gd T Cells
Are Sufficient to Promote Accelerated
TLR5-Mediated Malignant Progression
(A and B) Scatter plots (A) and median fluores-
cence intensity (MFI) (B) of intracellular galectin-1
expression of naive gd T cells sorted from pooled
axillary and inguinal lymph nodes of WT mice and
incubated directly (Cell:Cell) or separated by a
transwell insert (Transwell) for 5 days with MDSCs
sorted from the spleens of WT mice carrying
advanced autochthonous sarcomas or with bone
marrow-derived dendritic cells from naive WT
mice (BMDC).
(C) MFI of intracellular galectin-1 expression from
naive gd T cells cocultured with monocytic
(Ly6C+Ly6G-) and granulocytic (Ly6ClowLy6G+)
MDSCs from tumor-bearing WT mice or with total
MDSCs from tumor-bearing Tlr5/ mice. Poly-
morphonuclear leukocytes and monocytes were
sorted from the spleens of naive WT mice as
controls.
(D) Total galectin-1+ gd T cells in the draining
lymph nodes of WT MPKAS tumor-bearing mice
depleted of MDSCs (aGr1). Ig, immunoglobulin.
(E) Representative MPKAS tumor growth curve in
WT mice depleted of MDSCs.
(F) Representative tumor growth curve after
reconstitution of Trp53flx/flx;LSL-KrasG12D/+ mice
with bone marrow from WT or Lgals1/ mice
admixed (1:1) with Tcrd/ bone marrow, followed
by tumor initiation with adenovirus-Cre.
(G and H) gd T cells sorted from the draining lymph
nodes of WT or Tlr5/ mice bearing advanced
autochthonous sarcomas or D14 MPKAS tumors
and incubated at a 10:10:1 ratio with CellTracker
Violet-labeled endogenous tumor-reactive T cells
sorted from advanced sarcoma-bearing mice
incubated with MPKAS-pulsed dendritic cells (G)
or OT-1 T cells and BMDCs pulsed with full-length
ovalbumin (Ova) (H). Proliferation of tumor-reac-
tive T cells was measured by flow cytometric
analysis five days later.
Data are representative of two independent ex-
periments (five mice total). All data represent the
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
(Mann-Whitney test). See also Figure S3.
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same cytokine (Figure 5C).
Confirming the contribution of TLR5-dependent, tumor-
derived IL-6 to accelerated malignant growth, silencing IL-6
secretion in MPKAS tumor cells with two different constructs
resulted in significantly reduced growth of tumors in vivo,
whereas no differences were observed in vitro (Figure 5D; Fig-
ures S4E–S4G). Notably, mice growing IL-6-silenced sarcomas
induced significantly reduced serum IL-6 levels compared with
scrambled small hairpin RNA (shRNA)-expressing controlsCancer Cell 27, 27–40(Figure 5E). Decreased systemic IL-6
resulted in a significant reduction in
the accumulation of MDSCs and, corre-
spondingly, diminished production of
galectin-1 by gd T cells (Figures 5F and
5G) and decreased tumor-associatedMDSCs (Figure S4H). As a result, a significant increase in the
accumulation of IFNg-producing CD8 T cells was observed in
these tumors (Figure 5H; Figure S4I). Leukocyte-derived IL-6
also contributed to the systemic overexpression of IL-6 because
reconstitution of mice with IL-6-deficient bone marrow resulted
in a dramatic decrease in tumor growth (Figure 5I) and was
associated with decreased galectin-1+ gd T cells (Figure S4J).
Correspondingly, accelerated malignant progression in TLR5-
responsive hosts was completely abrogated upon IL-6 neutrali-
zation (Figure 5J). Together, these results demonstrate that, January 12, 2015 ª2015 Elsevier Inc. 33
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Figure 5. Tumor- and Leukocyte-Derived
IL-6 Drives Tumor Growth in TLR5-Respon-
sive Mice
(A) Growth kinetics of the mammary tumor cell line
A7C11 in WT or Tlr5/ mice.
(B) Serum IL-6 level of WT or Tlr5/mice bearing
advanced A7C11 (days 14–16) tumors.
(C) ELISA quantification of IL-6 production by the
indicated tumor cell lines 72 hr after overnight
incubation with 100 ng/ml recombinant mouse
IL-6 followed by washing of wells and the addition
of fresh media.
(D) Growth kinetics of MPKAS expressing IL-6
shRNA or scrambled shRNA in WT mice.
(E) Serum levels of IL-6 in WT mice 14 days after
injection with MPKAS expressing IL-6 shRNA or
scrambled control. Shown is one representative
of two independent experiments (eight mice per
group total).
(F–H) Proportions of tumor-associated Gr1+
CD11b+ MDSCs (F), galectin-1-producing gd
T cells (G), and IFNg-producing CD8 T cells (H)
from dissociated tumors (F) and tumor-draining
lymph-nodes (G and H) 14 days after injection of
WT mice with MPKAS tumor cell lines expressing
IL-6 shRNA or scrambled shRNA.
(I) Tumor kinetics of WT mice reconstituted with
IL-6-deficient (Il6/) or WT bone marrow (BM)
followed by challenge with the MPKAS tumor cell
line.
(J) Tumor kinetics of WT or Tlr5/ mice adminis-
tered IL-6 neutralizing antibody (a-IL-6) or isotype
control IgG challenged with MPKAS tumors.
All data represent the mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, NS, not significant
(Mann Whitney test). See also Figure S4.
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TLR5 Signaling Drives Tumor-Promoting Inflammationboth tumor- and leukocyte-derived IL-6 contribute to accelerate
the progression of IL-6-responsive tumors in TLR5-sufficient
hosts.
IL-17 Secreted through Interactions with Commensal
Bacteria Accelerates Malignant Progression Only
in IL-6-Unresponsive Tumors
These results suggest that only IL-6-responsive tumors undergo
TLR5-dependent accelerated growth, whereas IL-6-unrespon-
sive tumors rely on other signals. Supporting this proposition,
TLR5-deficient mice with advanced A7C11 tumors had signifi-
cantly higher serum levels of IL-17 compared with WT tumor-
bearing mice (Figure 6A). Increased systemic IL-17 was also
observed in TLR5-deficient mice growing orthotopic ovarian
cancer (Figure S5A) and MPKAS and autochthonous p53/K-
ras-dependent flank tumors (Figures 6B and 6C). Despite
increased systemic levels of IL-17 in Tlr5/ tumor-bearing
mice, we found only minor differences in the ratio of tumor-infil-34 Cancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc.trating IL-17+ cells, which included CD4
and gd T cells in similar proportions (Fig-
ures S5B and S5C).
To define the contribution of IL-17 to
accelerated tumor progression in TLR5-
deficient hosts, we neutralized IL-17 in
A7C11 tumor-challenged Tlr5/ and
WT littermates. Blockade of IL-17 abrogated differences in the
progression of these tumors inWT versus Tlr5/ hosts, resulting
in a significant reduction of tumor burden and growth kinetics in
Tlr5/ mice (Figure 6D; Figure S5D).
In contrast, IL-17 neutralization had no effect in the progres-
sion of IL-6-dependent MPKAS tumors (Figure 6E; Figure S5E).
Remarkably, silencing IL-6 production in the same tumor cells
was sufficient to render sarcomas sensitive to the tumor-pro-
moting activity of IL-17 because IL-17 blockade reduced malig-
nant progression in otherwise identical tumors transduced with
IL-6-shRNA (Figure 6F). Consistent with the elevation of sys-
temic IL-17 in all Tlr5/ tumor-bearing mice, IL-6 silencing in
MPKAS sarcomas was sufficient to reverse the effects of TLR5
signaling on malignant evolution because the same tumors that
previously grew faster in WT hosts started progressing more
rapidly in Tlr5/ mice when IL-6 was silenced (Figure 6G).
Therefore, although IL-6 is systemically upregulated in IL-6-
responsive tumors through TLR5 signaling and typically
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Figure 6. Tumor Growth for IL-6-Unrespon-
sive Tumors Is Mediated by IL-17 Induced
by Interactions with Commensal Microbiota
(A–C) Serum levels of IL-17 from WT or Tlr5/
mice bearing advanced A7C11 mammary tumors
(A), advanced MPKAS tumors (B), or advanced
autochthonous sarcomas from naive controls (C).
(D) A7C11 growth kinetics in WT and Tlr5/ mice
administered IL-17 neutralizing antibody (a-IL-17)
or Ig control (IgG).
(E) MPKAS tumor kinetics in WT or Tlr5/ mice
treated with a-IL-17 or IgG.
(F) Growth kinetics of MPKAS tumors expressing
IL-6 shRNA or scrambled shRNA in Tlr5/ mice
administered a-IL-17 or IgG.
(G) Growth kinetics of MPKAS expressing IL-6
shRNA or scrambled shRNA in Tlr5/ and WT
mice and representative resected tumors from
Tlr5/ mice.
(H) Serum levels of IL-17 in ABX or vehicle-treated
MPKAS or A7C11 tumor-bearing mice 14 days
(MPKAS) or 16 days (A7C11) after tumor initiation.
(I) Growth kinetics of A7C11 tumors from WT and
Tlr5/ mice treated with ABX or vehicle.
All data are representative of at least two repeti-
tions with at least four animals per group. All data
represent the mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 using Mann-Whitney test. See also
Figure S5.
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hosts, IL-17 accelerates malignant progression in IL-6-unre-
sponsive tumors. Because IL-17 is systemically higher in
TLR5-deficient, tumor-bearing hosts, the progression of tumors
associated with relatively low levels of IL-6 is accelerated.
Notably, antibiotic depletion of commensal bacteria also
induced a significant decrease in serum IL-17 levels and, corre-
spondingly, reduced IL-17 producing cells in the draining lymph
nodes of Tlr5/ tumor-bearing mice (Figure 6H; Figure S5F),
resulting in the complete abrogation of differences in tumor
progression between Tlr5/ and WT littermates (Figure 6I;
Figure S5G). Together, these results indicate that the balance
of IL-6 and IL-17 influence the outcome of malignant progres-
sion. Because IL-17 is overproduced in TLR5-deficient, tumor-
bearing individuals, in the absence of IL-6, this cytokine pre-
dominately drives tumor-promoting inflammation. These results
demonstrate that both IL-6- and IL-17-driven inflammatoryCancer Cell 27, 27–40macro- and microenvironments are con-
trolled by the commensal microbiota
and influence malignant progression.
TLR5-Deficient Breast Cancer
Patients Show Accelerated
Malignant Progression and
Upregulation of IL-17 in the TME
To substantiate the relevance of our
mechanistic observations, we first con-
firmed that CD45+CD14+ myeloid leuko-
cytes sorted from freshly dissociated
human ovarian tumors of three TLR5R392X
heterozygous carriers showed negligibleinduction of IL-8 transcript levels in response to flagellin
compared with the same cell population sorted from three
patients homozygous for the ancestral allele (Figure 7A).
These results corroborate previous reports demonstrating that
TLR5R392X carriers are functionally unable to respond to bacterial
flagellin (Gewirtz et al., 2006; Hawn et al., 2003). Most impor-
tantly, a survival analysis performed from fully or partially
sequenced samples of estrogen receptor-positive (ER+) breast
cancer patients from The Cancer Genome Atlas (TCGA) data
sets identified a significantly poorer outcome for carriers of
the TLR5R392X allele compared with patients homozygous for
the ancestral TLR5 allele (Figure 7B).
Supporting the relevance of our observations in murine tumor
models, IL-17A transcript levels in our ER+ breast cancer and
ovarian carcinoma specimens were also significantly higher in
TLR5R392X carriers compared with control patients homozygous
for the ancestral allele (Figure 7C). Both gd and ab (CD3+gd TCR–), January 12, 2015 ª2015 Elsevier Inc. 35
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Figure 7. TLR5-Deficient Patients Diagnosed with Breast Cancer
Have Accelerated Malignant Progression and Increased Intratu-
moral IL-17 Levels
(A) CXCL8 transcript levels in CD14+CD45+ myeloid cells sorted from three
heterozygous TLR5R392X or three TLR5-responsive advanced ovarian tumors
and incubated with 500 ng/ml of flagellin for 72 hr. CXCL8 transcript levels
were calculated relative to 18S expression.
(B) Survival analysis of TCGA data sets for ER+ breast cancer. Differences in
overall survival were calculated with log rank.
(C and D) Quantification of IL17A (C) or IL6 (D) transcripts relative to 18S
expression in nine frozen ER+ breast tumor specimens from TLR5R392X car-
riers, R10 randomly selected ER+ breast tumors from patients homozygous
for the ancestral allele, five to six stage III/IV ovarian carcinoma specimens
from TLR5R392X carriers, and R 15 randomly selected ovarian carcinoma
specimens homozygous for the ancestral allele.
(E) Serum IL-6 levels in patients homozygous for the ancestral allele of TLR5
diagnosed with ER+ breast carcinoma versus ovarian carcinoma.
All data represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (Mann-
Whitney test). See also Figure S6.
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TLR5 Signaling Drives Tumor-Promoting InflammationT cells contributed to IL-17 production in breast and ovarian
tumors (Figures S6A and S6B). However, significant differences
in IL-6 transcript levels were only observed between TLR5-36 Cancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc.responsive and nonresponsive ovarian tumor specimens but
not between TLR5-responsive and nonresponsive ER+ breast
tumor specimens (Figure 7D), further supporting the contribution
of tumor-derived IL-6 to differences in overall tumor-promoting
inflammation. Additionally, we found much lower levels of circu-
lating IL-6 in 20 available serum samples from ER+ breast cancer
patients compared with sera from 12 available ovarian cancer
patients (all of them TLR5-responsive; Figure 7E). These data
further support the fact that, in hosts where TLR5-dependent
IL-6 does not dominate systemic tumor-promoting inflammatory
responses through dramatic systemic upregulation, tumors
grow faster in the presence of IL-17 overexpression, which is
higher in the absence of TLR5 signaling. Together, these studies
demonstrate that a common genetic polymorphism, present
in >7% of individuals in the general population (Hawn et al.,
2003), influences systemic inflammatory responses and deter-
mines the outcome of breast cancer patients.
Higher Proportions of Long-Term Survivors among
TLR5-Defective Ovarian Cancer Patients
To further investigate the link between IL-6 upregulation and
accelerated tumor progression in the presence of TLR5
signaling, we next analyzed ovarian cancer TCGA data sets. A
total number of 25 TLR5R392X patients with outcome and deep
sequencing information was insufficient to identify significant
differences in overall survival compared with homozygous
carriers of the ancestral allele. However, the proportion of
long-term survivors (R6 years after the ovarian cancer diag-
nosis) was significantly higher among TLR5R392X carriers (but
not carriers of other nonfunctional polymorphisms; Figures 8A
and 8B), indicating that, as in our orthotopic ovarian preclinical
model, TLR5 signaling drives accelerated malignant progression
in ovarian cancer.
As in our murine models, the expression of immunosuppres-
sive galectin-1 was significantly higher in TLR5-responsive
ovarian cancer patients from our tumor bank, at both transcript
and protein levels (Figures 8C and 8D). Furthermore, we found
that, in multiple samples, CD3+CD4-CD8- gd T cells outnum-
bered Foxp3+ regulatory T cells in the ovarian cancer micro-
environment, representing up to 6% of tumor-infiltrating
lymphocytes, as detected by histology (Figure 8E and data
not shown) and flow cytometry (Figure 8F). At least 20% of
ovarian cancer-infiltrating gd T cells, which predominantly
represent peripheral blood-derived Vg9+ lymphocytes, pro-
duced significant levels of galectin-1 (Figure 8F). Further sup-
porting the relevance of our observations on the mechanistic
role of gd T cells in the TME, tumors from patients carrying
TLR5R392X contained a significantly lower number of galectin-
1-producing gd T cells (Figure 8G) compared with patients
homozygous for the ancestral allele. In addition, gd T cells in
tumors from TLR5-responsive patients had significantly higher
levels of intracellular galectin-1 on a per-cell basis (Figure 8H)
and at significantly higher levels than in tumor-associated
MDSCs (Figures S7A and S7B). Nevertheless, higher propor-
tions of galectin-1+ myeloid leukocytes were also found in
dissociated tumors from patients with the ancestral TLR5
allele (Figure S7C). Therefore, supporting the relevance of our
preclinical models, these findings reveal that a frequent poly-
morphism abrogating TLR5 responses to flagellin profoundly
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Figure 8. Higher Proportions of Long-Term
Survivors and Decreased Galectin-1
Expression Are Found in TLR5-Deficient
Patients Diagnosed with Ovarian Cancer
(A) Survival analysis of TCGA data sets for ovarian
cancer. The difference was calculated with log
rank.
(B) Fisher’s exact test of the proportions of ovarian
cancer patients surviving longer than or equal to
6 years after initial diagnosis with or without the
TLR5R392X polymorphism or with or without the
nondeleterious TLR5F822L polymorphism.
(C) Transcript levels of LGALS1 relative to 18S
levels from six ovarian tumor samples with
TLR5R392X and 91 randomly selected ovarian
tumor samples homozygous for the ancestral
allele of TLR5.
(D) Galectin-1 protein expression of 5 TLR5R392X
ovarian tumor samples and four randomly
selected ovarian tumor samples from patients
homozygous for the ancestral allele of TLR5.
Shown is a corresponding densitometric analysis
of band intensities for galectin-1 normalized to
vinculin.
(E) gd T cell immunohistochemistry from a frozen
ovarian tumor specimen homozygous for the
TLR5 ancestral allele. Scale bars, 100 mm.
(F) Representative gating strategy for flow cyto-
metric analysis of galectin-1-expressing, tumor-
infiltrating gd T cells. Numbers represent the
proportions of live cells gated from CD45+CD3+gd
TCR+ tumor-associated microenvironmental leu-
kocytes compared with the isotype control.
(G) Frequency of galectin-1-producing gd T cells in
the ovarian cancer microenvironment from three
ovarian tumors from TLR5R392X carriers, PBMCs
from four healthy donors, and 12 randomly
selected ovarian tumor samples from patients
homozygous for the ancestral allele.
(H) Histogram of galectin-1 expression from tu-
mor-associated gd T cells from the three available
disassociated ovarian tumor samples from
TLR5R392X carriers and three randomly selected
ovarian tumor samples from patients homozygous
for the ancestral allele of TLR5.
All data represent themean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001 (Mann-Whitney test). See also
Figure S7.
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mors and, subsequently, their clinical progression.
DISCUSSION
Our study demonstrates that TLR5 recognition of commensal
microbiota regulates systemic tumor-promoting inflammation
and, subsequently, extramucosal malignant progression. In
some tumors, TLR5 signaling drives the systemic upregulation
of IL-6, promoting MDSC mobilization, induction of suppressive
galectin-1-producing gd T cells and, subsequently, accelerated
tumor growth. Accordingly, most tumors tested progressed
significantly more slowly in TLR5-deficient individuals. Incontrast, IL-17 is commonly upregulated in TLR5-deficient,
tumor-bearing hosts but only drives accelerated tumor growth
in systems where tumor cells are poorly responsive to IL-6.
Any differences in malignant evolution are completely abrogated
following depletion of commensal bacteria.
Interestingly, TLR5-dependent increased systemic IL-6 is
triggered during tumor initiation because it does not occur in
tumor-free hosts. TLR5-dependent tumor growth appears to
require IL-6 production by both hematopoietic and tumor cells
because only IL-6-responsive tumor models are able to induce
IL-6-driven MDSC mobilization and subsequent accelerated
tumor progression comparedwith TLR5-nonresponsive animals.
Accordingly, knockdown of IL-6 in IL-6-responsive tumor cellCancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc. 37
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responsive mice, which is associated with decreased serum
IL-6 and, subsequently, reduced mobilization of MDSCs and
diminished production of galectin-1 by gd T cells. Supporting
the crucial role of IL-6 in tumor-promoting inflammation, in
luminal (although not in triple-negative) breast tumors, where
systemic IL-6 is significantly lower (e.g., compared with ovarian
cancer patients) (Casanova et al., 2011), tumors grow faster
in TLR5-defective individuals because IL-17 overexpressed in
the TME drives tumor-promoting inflammation. The role of
IL-17 during tumor progression remains controversial because
it has a clear protective role during ovarian cancer progression
but is associated with malignant promotion in other tumors,
such as breast cancer (Kryczek et al., 2009; Wang et al., 2009).
In our preclinical models, IL-17 neutralization delayed tumor
growth only when IL-6 was systemically low but had no effect
on tumors that progress faster in TLR5-responsive individuals
in an IL-6-dependent manner. Of note, silencing IL-6 was suffi-
cient to transform IL-6-dependent, IL-17-insensitive tumors
that grow faster in TLR5-responsive hosts into tumors that
become sensitive to IL-17 neutralization and progress faster in
TLR5-deficient individuals. The effects of other inflammatory
cytokines, therefore, add another layer of complexity to the
role of IL-17 in cancer and provide an understanding for its
conflicting activities. Most importantly, all differences in tumor-
promoting inflammation and malignant progression are elimi-
nated upon depletion of the microbiota. We identified TLR5-
dependent microbiome-wide differences in the repertoire of
commensal bacteria that persisted after cohousing mice in the
same cage. The composition of the microbiota is therefore
different in the absence of TLR5 signaling, and this influences
tumor-promoting inflammation.
Our results also underscore the contribution of gd T cells to
immunosuppression in multiple tumors, including ovarian can-
cer. Although the regulatory activity of gd T cells in breast cancer
has been reported (Peng et al., 2007), the mediators of effector
T cell suppression remained elusive. We demonstrate that bulk
populations of galectin-1-secreting gd T cells suppress T cell
responses to potent antigens in vitro and that galectin-1 specif-
ically produced by tumor-derived gd T cells is sufficient to accel-
erate tumor growth in vivo. Galectin-1 has emerged as a crucial
driver of immunosuppression in multiple tumors (Rabinovich and
Croci, 2012). Secreted galectin-1 crosslinks cell surface glyco-
conjugates bearing multiple units of the N-acetyllactosamine
(Galb1-4-NAcGlc) disaccharide and selectively blunts Th1,
Th17, and CD8 effector T cell responses (Rubinstein et al.,
2004). Our study identifies gd T cells as a relevant source of
this tolerogenic factor in the TME.
Finally, the most significant conclusion of our study is that
frequent polymorphisms that abrogate TLR5 activity are asso-
ciated with the outcomes of cancer patients. TLR5-dependent
differences in survival are particularly striking for ER+ patients,
for whom a TLR5 deficiency is associated with accelerated
malignant progression. In contrast, in ovarian cancer patients
who have higher serum IL-6, TLR5 signaling has a negative effect
on the proportion of long-term survivors. Because at least 30%
of individuals in the general population are carriers of a limited
set of polymorphisms in multiple pattern recognition receptor
genes that could also influence tumor-promoting inflammation38 Cancer Cell 27, 27–40, January 12, 2015 ª2015 Elsevier Inc.(Casanova et al., 2011; Hugot et al., 2007), our study opens
avenues for understanding how differential inflammatory re-
sponses and, subsequently, dissimilar malignant progression
takes place in many cancer patients. Our work also provides
a rationale for manipulating the microbiota through antibiotic
treatment to modulate tumor-promoting inflammation.
EXPERIMENTAL PROCEDURES
Mice
Transgenic Krastm4Tyj and Trp53tm1Brn mice (Jackson et al., 2001; Jonkers
et al., 2001) were obtained from the National Cancer Institute (NCI) Mouse
Models of Human Cancers Consortium, brought to a full C57BL/6 background
(Scarlett et al., 2012), and bred to TLR5-deficient (Tlr5/) mice (B6.129S1-
Tlr5tm1Flv/J) (Cubillos-Ruiz et al., 2009). Galectin-1-deficient (Lgals1/) mice
were provided by G.A. Rabinovich at the Instituto de Biologı´a y Medicina
Experimental (IBYME-CONICET) Argentina and were originally generated by
F. Poirier (Jacques Monod Institut). gd T cell-deficient mice Tcrd/ mice
(B6.129P2-Tcrdtm1Mom/J) were obtained from The Jackson Laboratory and
bred to Tlr5/ mice. WT C57BL/6 mice were obtained from the NCI. OT1
C57BL/6-Tg (TcraTcrb)1100Mjb/J and IL-6-deficient (B6.129S2-IL6tm1kopf/J)
transgenic mice were obtained from The Jackson Laboratory. All animals
were maintained in pathogen-free barrier facilities. All experiments were
conducted according to the approval of the Institutional Animal Care and
Use Committee of the Wistar Institute.
Genetic Tumor Models and Cell Lines
Autochthonous p53/Kras flank sarcomas were initiated by subcutaneous
delivery of 2.5 3 108 plaque-forming units of adenovirus-cre (Gene Transfer
Vector Core, University of Iowa) into transgenic mice. For the mixed bone
marrow chimeras, transgenic mice were irradiated for two consecutive days
with 650 rads, followed by reconstitution with WT or Lgals1/ bone marrow
mixed at a 1:1 ratio with Tcrd/ bone marrow. Flank tumors were initiated in
reconstituted animals 6 weeks following engraftment. ID8 cells were provided
by K. Roby (Department of Anatomy and Cell Biology, University of Kansas)
and retrovirally transduced to express Defb29 and Vegf-a (Conejo-Garcia
et al., 2004). MPKAS cells were generated from passaging sorted tumor cells
(CD45-negative) derived from mechanically disassociated autochthonous
p53/Kras axillary sarcomas. Mouse ovarian tumor UPK10 cells were generated
by culturing a mechanically dissociated p53/Kras primary ovarian tumor mass
(Scarlett et al., 2012). The A7C11 and BRPKP110 primary mammary tumor
cell linesweregeneratedbypassagingsorted tumorcells frommechanicallydis-
associated p53/Kras (A7C11) or p53/Kras/myristoylated p110a (BRPKP110)
mammary carcinomas (Rutkowski et al., 2014). Flank tumors with MPKAS- or
MPKAS shRNA-expressing clones (1 3 105 cells), UPK10, and ID8-Vegf-
Defb29 (106) were admixed at a 1:1 ratio with growth factor-reduced Matrigel
(BDBiosciences) and injected into theaxillary flank.A7C11 tumorswere initiated
by injecting 23 104 cells into the axillary flank. Intraperitoneal ID8-Vegf-Defb29
tumors were initiated by intraperitoneal injection of 2 3 106 cells. The tumor
volume was calculated as: 0.53 (L3W2), where L is length, and W is width.
Human Specimens
Human ovarian carcinoma tissues were procured under a protocol approved
by the Committee for the Protection of Human Subjects at Dartmouth-
Hitchcock Medical Center (#17702) and under a protocol approved by the
Institutional Review Board at Christiana Care Health System (#32214) and
the Institutional Review Board of The Wistar Institute (#21212263). Human
breast tumor tissues and sera were obtained under a protocol approved by
the Institutional Review Board of the University of Pennsylvania (#805139)
and the Institutional Review Board of The Wistar Institute (#21204259).
Informed consent was obtained from all subjects.
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